Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Drug Insights
4 min read
An In-depth Analysis of Nebivolol hydrochloride's R&D Progress
9 November 2023
This article summarized the latest R&D progress of Nebivolol hydrochloride, the Mechanism of Action for Nebivolol hydrochloride, and the drug target R&D trends for Nebivolol hydrochloride.
Bio Sequence
2 min read
Biological Glossary | What is Chemical Modification?
9 November 2023
Chemical modifications in biology refer to the changes in biomolecular structure and function brought about by the addition or removal of modifying elements.
Latest Hotspot
3 min read
IDRx shares initial findings from its ongoing Phase 1 StrateGIST trial at CTOS 2023, illustrating the promise of IDRX-42 for GIST patients
9 November 2023
IDRx, Inc. has reported initial clinical results from its ongoing Phase 1 StrateGIST trial of IDRX-42. This trial is for patients with metastatic and/or inoperable gastrointestinal stromal tumors who have previously received at least one tyrosine kinase inhibitor therapy regime, now testing a higher dosage.
Bio Sequence
3 min read
Research, Patent, and Literature Data behind the Early ADC Drug ORM-6151 Purchased by Bristol-Myers Squibb at a Huge Cost
9 November 2023
ORM-6151 is a monoclonal antibody drug that targets CD33 and GSPT1, developed by Orum Therapeutics.
Latest Hotspot
3 min read
Fresenius Kabi introduces Tyenne*, the inaugural EU-sanctioned tocilizumab biosimilar
9 November 2023
Fresenius Kabi made an announcement about the introduction of Tyenne®, its tocilizumab biosimilar which references the RoActemra® (tocilizumab) in the European Union.
Drug Insights
4 min read
Nelarabine: Detailed Review of its Transformative R&D Success, Mechanism of Action, and Drug Target
9 November 2023
This article summarized the latest R&D progress of Nelarabine, the Mechanism of Action for Nelarabine, and the drug target R&D trends for Nelarabine.
Hot Spotlight
6 min read
Patent Analysis of Jiangsu Hengrui's PARP1 Inhibitor HRS-1167
8 November 2023
In late October, Hengrui and Merck agreed on a €1.4 billion transaction, with a first payment of €160 million. The deal mainly involves Hengrui's self-developed PARP1 inhibitor HRS-1167 and Claudin-18.2 ADC SHR-A1904.
Drug Insights
4 min read
Lotilaner Unveiled: A Detailed Overview of its Revolutionary R&D Breakthroughs
8 November 2023
This article summarized the latest R&D progress of Lotilaner, the mechanism of action for Lotilaner, and the drug target R&D trends for Lotilaner.
Latest Hotspot
3 min read
2023 SITC | Junshi Biosciences announced the latest clinical results of PD-1 inhibitor Toripalimab
8 November 2023
Recent trial findings of Junshi Biosciences' Toripalimab and Cetuximab combo for treating R/M-HNSCC were shared at the 38th annual SITC meeting in 2023.
Drug Insights
4 min read
Unleashing the Power of Mebeverine Hydrochloride: A Comprehensive Review on R&D Breakthroughs
8 November 2023
This article summarized the latest R&D progress of Mebeverine Hydrochloride, the mechanism of action for Mebeverine Hydrochloride, and the drug target R&D trends for Mebeverine Hydrochloride.
Valuable Targets
6 min read
Analysis on the Research Progress of D2 Receptor Agonist
8 November 2023
The D2 receptor is a type of dopamine receptor found in the human body. It plays a crucial role in various physiological and neurological processes.
Drug Insights
4 min read
A Comprehensive Review of Melarsoprol's R&D Innovations and Drug Target Mechanism
8 November 2023
This article summarized the latest R&D progress of Melarsoprol, the Mechanism of Action for Melarsoprol, and the drug target R&D trends for Melarsoprol.